Jun 6 |
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
|
Jun 6 |
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
|
Jun 6 |
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
|
Jun 6 |
Hedge Fund Favorites: 7 Stocks to Buy When You’re Feeling Jittery
|
Jun 6 |
AbbVie treats first subject in Phase III multiple myeloma drug trial
|
Jun 5 |
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
|
Jun 5 |
AbbVie doses first patient in phase 3 trial of multiple myeloma asset
|
Jun 5 |
2 High-Yield Dividend Stocks to Buy Right Now
|
Jun 5 |
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
|
Jun 5 |
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
|